Diagnostic markers based on a computational model of lipoprotein metabolism

Table 3 Subject groups used

Subject group	Number of subjects	Ref.	Included in 'normo-lipidemic' group	Included in 'dys-lipidemic' group
Normolipidemic controls	3 (in: N1, N3, N5)	[19]	x
Normolipidemic controls	6	[20]	x
Normolipidemic controls: apoE 3/3 subjects.	5	[17]	x
Normolipidemic controls	9	[21]	x
All subjects	12	[22]	x
phenotype 'A' (large LDL particle size)	9	[18]	x
mixed dyslipidemia prior to treatment (Baseline)	5 (in: P2, P3, P5, P7, P8)	[24]		x
mixed dyslipidemia prior to treatment (Baseline)	11	[25]		x
kidney patients	9	[21]		x
hypothyroid subjects before and during T4 therapy	10 (excluded before T4: 6; during T4: 3)	[26]		x
HIV treatment-associated hyperlipidemic subjects	5	[23]		x
phenotype 'B' subjects, with small LDL particle size	4 (in: subjects 17-20)	[18]		x
LPL -/-	3	[16]
apoE 2/2	4	[17]
apoE 4/4	5	[17]
homozygous familial hypercholesterolemia	3 (in: FH1, FH2, FH4)	[19]
familial defective apoB	3	[29]
S447X; a single nucleotide polymorphism in the LPL gene	5	[30]
Total used for normolipidemic group	44
Total used for dyslipidemic group	44

Subject groups used for normolipidemia, dyslipidemia, and genetic disorders. If subjects needed to be excluded from a group because of a lack of steady state in the data (in- and efflux balance), individual subjects are mentioned.